Volume Alert - TEVA 57.21 Teva Pharmaceutical Industries Ltd $TEVA Hit a high today of 57.34 Closing the day 10:30 at 57.21 -0.04 -0.07% With a day low of 56.98 and a total volume of 1,095,383.
TEVA Recent Posts: http://investorshangout.com/Teva-Pharmaceutic...EVA-55623/
TEVA Teva Pharmaceutical Industries Ltd Recent Headline News
FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - 28 mins ago
MNK: 86.68 (+0.70), EGLT: 6.52 (+0.28), ZGNX: 1.20 (-0.01), PFE: 30.44 (unch), TEVA: 57.09 (-0.16), ABBV: 65.38 (-0.12), ALKS: 55.00 (+0.74), ACUR: 0.53 (unch)
Biotech's 3 Most Influential CEOs
Motley Fool Staff - Motley Fool - Thu Nov 20, 9:20AM CST
Who's the most influential CEO in the biotech business? The answer to that question might be largely a matter of opinion; however, there are definite standouts in the sector -- three of whom receive an enthusiastic "thumbs-up" from these Motley Fool...
OPK: 8.13 (-0.03), GILD: 101.32 (-1.02), TEVA: 57.09 (-0.16), SNY: 47.08 (-1.01)
Biogen Idec, PML Deaths, And Hemophilia Therapies
William Meyers - at Seeking Alpha - Wed Nov 19, 2:01PM CST
BIIB: 300.32 (-3.29), TEVA: 57.09 (-0.16)
Teva unveils new liquid formulation of TREANDA (bendamustine HCI) Injection in US
M2 - Wed Nov 19, 6:11AM CST
Pharmaceutical company Teva Pharmaceutical Industries (NYSE:TEVA) disclosed on Tuesday the commercial launch of the liquid formulation of TREANDA (bendamustine HCI) Injection in the US.
TEVA: 57.09 (-0.16)
Tracking George Soros's Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Wed Nov 19, 4:48AM CST
HLF: 39.64 (+0.98), VIPS: 22.82 (+0.38), CNX: 41.48 (+0.71), MON: 119.94 (+0.38), DAL: 44.09 (-0.36), CHTR: 159.51 (+0.88), ESNT: 23.01 (+0.57), CNP: 24.38 (unch), INTC: 35.46 (+1.11), GOOG: 534.80 (-2.19), CTXS: 64.76 (+0.14), MSI: 65.89 (-0.05), EEM: 41.19 (-0.01), SPY: 205.47 (+0.25), AAL: 44.36 (+0.26), ABBV: 65.38 (-0.12), GDX: 19.63 (+0.44), MSFT: 48.40 (+0.18), SYK: 89.67 (+0.03), PSX: 77.43 (+1.66), FB: 73.53 (+0.20), HAL: 49.12 (+0.69), PLCM: 13.18 (+0.08), LVLT: 49.21 (+0.12), TEVA: 57.09 (-0.16), AIG: 54.46 (+0.44), IWM: 116.03 (+0.88), DOW: 51.39 (-0.09), LUK: 24.15 (-0.09), VRX: 142.56 (+0.09), LBTYK: 44.90 (-0.29), CLI: 18.98 (-0.01), CZR: 15.11 (+0.74), CACQ: 10.41 (+0.22), EGN: 68.25 (+1.95), TIBX: 23.73 (+0.03), LBTYA: 46.00 (-0.28), ALLE: 54.13 (+0.13), SEMG: 80.36 (-0.31), AGRO: 9.30 (-0.02), GOOGL: 544.11 (-3.09), NICE: 46.60 (+0.74), AAPL: 116.48 (+1.81), WAG: 67.39 (-0.40), XLE: 87.03 (+0.75), WNR: 42.00 (-0.19), PVA: 8.15 (+0.23), DISH: 72.83 (-1.83), EQT: 95.67 (-0.27), LORL: 73.72 (+0.31), BIDU: 239.31 (-1.11), QQQ: 103.62 (+0.41), GM: 31.97 (-0.18), HUB.B: 108.67 (-0.46), BABA: 111.08 (+2.26)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 259.65 (-6.39), QLTI: 3.93 (-0.06), VRX: 142.60 (+0.13), AGN: 209.93 (-2.66), SHPG: 211.14 (+3.56), AUXL: 33.18 (+0.15), ABBV: 65.38 (-0.12), SNY: 47.09 (-1.00), ABT: 43.60 (+0.17), ENDP: 69.51 (+0.50), AKRX: 37.80 (-0.38), PFE: 30.44 (unch), INCY: 71.12 (-0.18), SLXP: 103.23 (-0.40), MYL: 55.31 (-0.37), AMGN: 164.24 (+1.60), LLY: 66.81 (-0.40), GSK: 46.52 (+0.27), BMY: 58.71 (-0.10), ACHN: 13.18 (+0.27), MRK: 59.27 (-0.37), AZN: 74.23 (-1.15), ICPT: 155.52 (-0.41), TEVA: 57.09 (-0.16), NVS: 95.50 (-0.23)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 259.65 (-6.39), QLTI: 3.93 (-0.06), VRX: 142.60 (+0.13), AGN: 209.93 (-2.66), SHPG: 211.14 (+3.56), AUXL: 33.18 (+0.15), ABBV: 65.38 (-0.12), SNY: 47.09 (-1.00), ABT: 43.60 (+0.17), ENDP: 69.51 (+0.50), AKRX: 37.80 (-0.38), PFE: 30.44 (unch), INCY: 71.12 (-0.18), SLXP: 103.23 (-0.40), MYL: 55.31 (-0.37), AMGN: 164.24 (+1.60), LLY: 66.81 (-0.40), GSK: 46.52 (+0.27), BMY: 58.71 (-0.10), ACHN: 13.18 (+0.27), MRK: 59.27 (-0.37), AZN: 74.23 (-1.15), ICPT: 155.52 (-0.41), TEVA: 57.09 (-0.16), NVS: 95.50 (-0.23)
The Passive DGI Portfolio: Quarterly Portfolio Update
Financially Free Investor - at Seeking Alpha - Tue Nov 18, 2:26PM CST
DWX: 45.69 (+0.07), LMT: 185.78 (-0.22), CLX: 100.57 (-0.23), MDT: 71.73 (-0.03), MON: 119.94 (+0.38), UTX: 108.73 (+0.07), WMT: 84.51 (-0.48), O: 45.90 (unch), INTC: 35.46 (+1.11), PEP: 98.05 (-0.36), JNJ: 108.15 (-0.61), CDK: 38.02 (-0.38), QCOM: 70.52 (+0.05), MSFT: 48.40 (+0.18), WAG: 67.39 (-0.40), APD: 142.50 (+0.36), AVIV: 32.73 (+0.23), ABT: 43.60 (+0.17), HCP: 43.10 (-0.12), EMR: 64.38 (+0.23), COP: 72.99 (+0.86), MO: 48.81 (-0.33), WM: 48.33 (-0.23), ADP: 84.17 (-0.10), OHI: 37.26 (+0.26), MCD: 96.87 (+0.31), TEVA: 57.09 (-0.16), PG: 88.52 (-0.21), CVX: 116.70 (+0.23), AFL: 59.00 (-0.06), CL: 68.08 (-0.21)
Personal Dividend Growth Portfolio Update: November 2014
FinancialStorm - at Seeking Alpha - Tue Nov 18, 12:53PM CST
MDT: 71.73 (-0.03), NKSH: 30.35 (-0.21), DLR: 68.38 (-0.17), MBVT: 28.33 (-0.28), O: 45.90 (unch), INTC: 35.46 (+1.11), WEC: 48.57 (-0.08), BNS: 61.75 (+0.37), VTR: 68.31 (-0.21), COH: 36.39 (+0.95), MAT: 31.79 (+0.70), CMI: 144.15 (+1.01), DE: 85.82 (-0.51), MSFT: 48.40 (+0.18), WAG: 67.39 (-0.40), WFM: 47.73 (-0.05), NSC: 115.17 (unch), LLTC: 43.51 (+0.01), EMR: 64.38 (+0.23), VOD: 35.42 (-0.27), NEE: 102.83 (-0.88), BAX: 71.76 (-0.70), OHI: 37.26 (+0.26), VYM: 69.69 (+0.12), RBA: 25.65 (+0.10), TEVA: 57.09 (-0.16), PG: 88.52 (-0.21), VZ: 50.23 (-0.26), AFL: 59.00 (-0.06), NVS: 95.50 (-0.23)
Teva wins Actonel patent appeal
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 11:06AM CST
ACT: 259.65 (-6.39), MYL: 55.31 (-0.37), TEVA: 57.08 (-0.17)
Why Mylan Will Continue To Soar
Main Street Wins - at Seeking Alpha - Tue Nov 18, 8:50AM CST
MYL: 55.31 (-0.37), TEVA: 57.08 (-0.17)
Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - Tue Nov 18, 8:29AM CST
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 259.65 (-6.39), PFE: 30.44 (unch), TEVA: 57.08 (-0.17)
/R E P E A T -- Teva Canada Announces the Launch of (Pr)Teva-Celecoxib, a generic of (Pr)Celebrex®/
CNW Group - Tue Nov 18, 8:00AM CST
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved its application for the generic version of (Pr)Celebrex(®) for the symptomatic relief associated with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. (Pr)Teva-Celecoxib is also indicated for the short-term (≤ 7 days) management of moderate to severe acute pain in adults in conditions such as musculoskeletal and/or soft tissue trauma including sprains, postoperative orthopaedic, and pain following dental extraction.
TEVA: 57.08 (-0.17)
Teva Launches Liquid Formulation of TREANDA(R) (bendamustine HCI) Injection in U.S.
Business Wire - Tue Nov 18, 7:02AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the commercial availability of a liquid formulation of TREANDA(R) (bendamustine HCI) Injection. This new liquid formulation removes the step of reconstituting lyophilized powder with sterile water prior to adding the required dose of medicine to the infusion bag and administering to a patient. By eliminating the need for reconstitution, preparation time for healthcare professionals is reduced.
TEVA: 57.08 (-0.17)
Teva, Fedex Shares Look Fantastic, Arch Coal Headed Lower
at The Street - Mon Nov 17, 4:36PM CST
Shares of Teva remain relatively inexpensive despite the stock's sharp move higher this year, said Andrew Ver Planck, portfolio manager for the MainStay International Opportunities Fund.
FDX: 172.42 (+0.74), ACI: 2.46 (+0.16), TEVA: 57.08 (-0.17)
Teva Canada Announces the Launch of (Pr)Teva-Celecoxib, a generic of (Pr)Celebrex®
CNW Group - Mon Nov 17, 4:16PM CST
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved its application for the generic version of (Pr)Celebrex(®) for the symptomatic relief associated with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. (Pr)Teva-Celecoxib is also indicated for the short-term (≤ 7 days) management of moderate to severe acute pain in adults in conditions such as musculoskeletal and/or soft tissue trauma including sprains, postoperative orthopaedic, and pain following dental extraction.
TEVA: 57.08 (-0.17)
Teva Pharmaceutical Industries Earnings Review: 18 Days after Announcement Shares Up 1.1% (TEVA)
Comtex SmarTrend(R) - Mon Nov 17, 2:41PM CST
18 days ago, on October 30th, 2014, Teva Pharmaceutical Industries (NASDAQ:TEVA) reported its earnings. Analysts, on average, expected earnings of $1.24 per share on sales of $5.1 billion. Teva Pharmaceutical Industries actually reported a break-even quarter on sales of $5.1 billion, missing EPS estimates by $1.24 and missing revenue estimates by $37.1 million. Since the company's report, shares of Teva Pharmaceutical Industries have risen from $56.47 to $57.07, representing a gain of 1.1% in the past 18 days.
TEVA: 57.08 (-0.17)
Look for Shares of Teva Pharmaceutical Industries to Potentially Rebound after Yesterday's 2.17% Sell Off
Comtex SmarTrend(R) - Thu Nov 13, 4:11PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.02 to a high of $58.50. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $57.46 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 57.08 (-0.17)
Teva Pharmaceutical Industries Falls 2.17% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 13, 4:11PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.02 to a high of $58.50. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $57.46 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 57.08 (-0.17)
TEVA: Copaxone Patent Expiry Worries Are Overblown
Alpha Gen Capital - at Seeking Alpha - Tue Nov 11, 2:52PM CST
TEVA: 57.08 (-0.17)
TEVA Recent Posts: http://investorshangout.com/Teva-Pharmaceutic...EVA-55623/
TEVA Teva Pharmaceutical Industries Ltd Recent Headline News
FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - 28 mins ago
MNK: 86.68 (+0.70), EGLT: 6.52 (+0.28), ZGNX: 1.20 (-0.01), PFE: 30.44 (unch), TEVA: 57.09 (-0.16), ABBV: 65.38 (-0.12), ALKS: 55.00 (+0.74), ACUR: 0.53 (unch)
Biotech's 3 Most Influential CEOs
Motley Fool Staff - Motley Fool - Thu Nov 20, 9:20AM CST
Who's the most influential CEO in the biotech business? The answer to that question might be largely a matter of opinion; however, there are definite standouts in the sector -- three of whom receive an enthusiastic "thumbs-up" from these Motley Fool...
OPK: 8.13 (-0.03), GILD: 101.32 (-1.02), TEVA: 57.09 (-0.16), SNY: 47.08 (-1.01)
Biogen Idec, PML Deaths, And Hemophilia Therapies
William Meyers - at Seeking Alpha - Wed Nov 19, 2:01PM CST
BIIB: 300.32 (-3.29), TEVA: 57.09 (-0.16)
Teva unveils new liquid formulation of TREANDA (bendamustine HCI) Injection in US
M2 - Wed Nov 19, 6:11AM CST
Pharmaceutical company Teva Pharmaceutical Industries (NYSE:TEVA) disclosed on Tuesday the commercial launch of the liquid formulation of TREANDA (bendamustine HCI) Injection in the US.
TEVA: 57.09 (-0.16)
Tracking George Soros's Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Wed Nov 19, 4:48AM CST
HLF: 39.64 (+0.98), VIPS: 22.82 (+0.38), CNX: 41.48 (+0.71), MON: 119.94 (+0.38), DAL: 44.09 (-0.36), CHTR: 159.51 (+0.88), ESNT: 23.01 (+0.57), CNP: 24.38 (unch), INTC: 35.46 (+1.11), GOOG: 534.80 (-2.19), CTXS: 64.76 (+0.14), MSI: 65.89 (-0.05), EEM: 41.19 (-0.01), SPY: 205.47 (+0.25), AAL: 44.36 (+0.26), ABBV: 65.38 (-0.12), GDX: 19.63 (+0.44), MSFT: 48.40 (+0.18), SYK: 89.67 (+0.03), PSX: 77.43 (+1.66), FB: 73.53 (+0.20), HAL: 49.12 (+0.69), PLCM: 13.18 (+0.08), LVLT: 49.21 (+0.12), TEVA: 57.09 (-0.16), AIG: 54.46 (+0.44), IWM: 116.03 (+0.88), DOW: 51.39 (-0.09), LUK: 24.15 (-0.09), VRX: 142.56 (+0.09), LBTYK: 44.90 (-0.29), CLI: 18.98 (-0.01), CZR: 15.11 (+0.74), CACQ: 10.41 (+0.22), EGN: 68.25 (+1.95), TIBX: 23.73 (+0.03), LBTYA: 46.00 (-0.28), ALLE: 54.13 (+0.13), SEMG: 80.36 (-0.31), AGRO: 9.30 (-0.02), GOOGL: 544.11 (-3.09), NICE: 46.60 (+0.74), AAPL: 116.48 (+1.81), WAG: 67.39 (-0.40), XLE: 87.03 (+0.75), WNR: 42.00 (-0.19), PVA: 8.15 (+0.23), DISH: 72.83 (-1.83), EQT: 95.67 (-0.27), LORL: 73.72 (+0.31), BIDU: 239.31 (-1.11), QQQ: 103.62 (+0.41), GM: 31.97 (-0.18), HUB.B: 108.67 (-0.46), BABA: 111.08 (+2.26)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 259.65 (-6.39), QLTI: 3.93 (-0.06), VRX: 142.60 (+0.13), AGN: 209.93 (-2.66), SHPG: 211.14 (+3.56), AUXL: 33.18 (+0.15), ABBV: 65.38 (-0.12), SNY: 47.09 (-1.00), ABT: 43.60 (+0.17), ENDP: 69.51 (+0.50), AKRX: 37.80 (-0.38), PFE: 30.44 (unch), INCY: 71.12 (-0.18), SLXP: 103.23 (-0.40), MYL: 55.31 (-0.37), AMGN: 164.24 (+1.60), LLY: 66.81 (-0.40), GSK: 46.52 (+0.27), BMY: 58.71 (-0.10), ACHN: 13.18 (+0.27), MRK: 59.27 (-0.37), AZN: 74.23 (-1.15), ICPT: 155.52 (-0.41), TEVA: 57.09 (-0.16), NVS: 95.50 (-0.23)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 259.65 (-6.39), QLTI: 3.93 (-0.06), VRX: 142.60 (+0.13), AGN: 209.93 (-2.66), SHPG: 211.14 (+3.56), AUXL: 33.18 (+0.15), ABBV: 65.38 (-0.12), SNY: 47.09 (-1.00), ABT: 43.60 (+0.17), ENDP: 69.51 (+0.50), AKRX: 37.80 (-0.38), PFE: 30.44 (unch), INCY: 71.12 (-0.18), SLXP: 103.23 (-0.40), MYL: 55.31 (-0.37), AMGN: 164.24 (+1.60), LLY: 66.81 (-0.40), GSK: 46.52 (+0.27), BMY: 58.71 (-0.10), ACHN: 13.18 (+0.27), MRK: 59.27 (-0.37), AZN: 74.23 (-1.15), ICPT: 155.52 (-0.41), TEVA: 57.09 (-0.16), NVS: 95.50 (-0.23)
The Passive DGI Portfolio: Quarterly Portfolio Update
Financially Free Investor - at Seeking Alpha - Tue Nov 18, 2:26PM CST
DWX: 45.69 (+0.07), LMT: 185.78 (-0.22), CLX: 100.57 (-0.23), MDT: 71.73 (-0.03), MON: 119.94 (+0.38), UTX: 108.73 (+0.07), WMT: 84.51 (-0.48), O: 45.90 (unch), INTC: 35.46 (+1.11), PEP: 98.05 (-0.36), JNJ: 108.15 (-0.61), CDK: 38.02 (-0.38), QCOM: 70.52 (+0.05), MSFT: 48.40 (+0.18), WAG: 67.39 (-0.40), APD: 142.50 (+0.36), AVIV: 32.73 (+0.23), ABT: 43.60 (+0.17), HCP: 43.10 (-0.12), EMR: 64.38 (+0.23), COP: 72.99 (+0.86), MO: 48.81 (-0.33), WM: 48.33 (-0.23), ADP: 84.17 (-0.10), OHI: 37.26 (+0.26), MCD: 96.87 (+0.31), TEVA: 57.09 (-0.16), PG: 88.52 (-0.21), CVX: 116.70 (+0.23), AFL: 59.00 (-0.06), CL: 68.08 (-0.21)
Personal Dividend Growth Portfolio Update: November 2014
FinancialStorm - at Seeking Alpha - Tue Nov 18, 12:53PM CST
MDT: 71.73 (-0.03), NKSH: 30.35 (-0.21), DLR: 68.38 (-0.17), MBVT: 28.33 (-0.28), O: 45.90 (unch), INTC: 35.46 (+1.11), WEC: 48.57 (-0.08), BNS: 61.75 (+0.37), VTR: 68.31 (-0.21), COH: 36.39 (+0.95), MAT: 31.79 (+0.70), CMI: 144.15 (+1.01), DE: 85.82 (-0.51), MSFT: 48.40 (+0.18), WAG: 67.39 (-0.40), WFM: 47.73 (-0.05), NSC: 115.17 (unch), LLTC: 43.51 (+0.01), EMR: 64.38 (+0.23), VOD: 35.42 (-0.27), NEE: 102.83 (-0.88), BAX: 71.76 (-0.70), OHI: 37.26 (+0.26), VYM: 69.69 (+0.12), RBA: 25.65 (+0.10), TEVA: 57.09 (-0.16), PG: 88.52 (-0.21), VZ: 50.23 (-0.26), AFL: 59.00 (-0.06), NVS: 95.50 (-0.23)
Teva wins Actonel patent appeal
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 11:06AM CST
ACT: 259.65 (-6.39), MYL: 55.31 (-0.37), TEVA: 57.08 (-0.17)
Why Mylan Will Continue To Soar
Main Street Wins - at Seeking Alpha - Tue Nov 18, 8:50AM CST
MYL: 55.31 (-0.37), TEVA: 57.08 (-0.17)
Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - Tue Nov 18, 8:29AM CST
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 259.65 (-6.39), PFE: 30.44 (unch), TEVA: 57.08 (-0.17)
/R E P E A T -- Teva Canada Announces the Launch of (Pr)Teva-Celecoxib, a generic of (Pr)Celebrex®/
CNW Group - Tue Nov 18, 8:00AM CST
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved its application for the generic version of (Pr)Celebrex(®) for the symptomatic relief associated with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. (Pr)Teva-Celecoxib is also indicated for the short-term (≤ 7 days) management of moderate to severe acute pain in adults in conditions such as musculoskeletal and/or soft tissue trauma including sprains, postoperative orthopaedic, and pain following dental extraction.
TEVA: 57.08 (-0.17)
Teva Launches Liquid Formulation of TREANDA(R) (bendamustine HCI) Injection in U.S.
Business Wire - Tue Nov 18, 7:02AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the commercial availability of a liquid formulation of TREANDA(R) (bendamustine HCI) Injection. This new liquid formulation removes the step of reconstituting lyophilized powder with sterile water prior to adding the required dose of medicine to the infusion bag and administering to a patient. By eliminating the need for reconstitution, preparation time for healthcare professionals is reduced.
TEVA: 57.08 (-0.17)
Teva, Fedex Shares Look Fantastic, Arch Coal Headed Lower
at The Street - Mon Nov 17, 4:36PM CST
Shares of Teva remain relatively inexpensive despite the stock's sharp move higher this year, said Andrew Ver Planck, portfolio manager for the MainStay International Opportunities Fund.
FDX: 172.42 (+0.74), ACI: 2.46 (+0.16), TEVA: 57.08 (-0.17)
Teva Canada Announces the Launch of (Pr)Teva-Celecoxib, a generic of (Pr)Celebrex®
CNW Group - Mon Nov 17, 4:16PM CST
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved its application for the generic version of (Pr)Celebrex(®) for the symptomatic relief associated with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. (Pr)Teva-Celecoxib is also indicated for the short-term (≤ 7 days) management of moderate to severe acute pain in adults in conditions such as musculoskeletal and/or soft tissue trauma including sprains, postoperative orthopaedic, and pain following dental extraction.
TEVA: 57.08 (-0.17)
Teva Pharmaceutical Industries Earnings Review: 18 Days after Announcement Shares Up 1.1% (TEVA)
Comtex SmarTrend(R) - Mon Nov 17, 2:41PM CST
18 days ago, on October 30th, 2014, Teva Pharmaceutical Industries (NASDAQ:TEVA) reported its earnings. Analysts, on average, expected earnings of $1.24 per share on sales of $5.1 billion. Teva Pharmaceutical Industries actually reported a break-even quarter on sales of $5.1 billion, missing EPS estimates by $1.24 and missing revenue estimates by $37.1 million. Since the company's report, shares of Teva Pharmaceutical Industries have risen from $56.47 to $57.07, representing a gain of 1.1% in the past 18 days.
TEVA: 57.08 (-0.17)
Look for Shares of Teva Pharmaceutical Industries to Potentially Rebound after Yesterday's 2.17% Sell Off
Comtex SmarTrend(R) - Thu Nov 13, 4:11PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.02 to a high of $58.50. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $57.46 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 57.08 (-0.17)
Teva Pharmaceutical Industries Falls 2.17% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 13, 4:11PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.02 to a high of $58.50. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $57.46 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 57.08 (-0.17)
TEVA: Copaxone Patent Expiry Worries Are Overblown
Alpha Gen Capital - at Seeking Alpha - Tue Nov 11, 2:52PM CST
TEVA: 57.08 (-0.17)
